Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Products
Careers
Citizenship »
« Back
Insights
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Products
Careers
Citizenship »
« Back
Insights
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Investor Overview

Stock quote

VOLUME:

View stock performance »

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Press Releases

January 20, 2021

Aclaris Announces Pricing of Public Offering of Common Stock

January 19, 2021

Aclaris Announces Proposed Public Offering of Common Stock

January 19, 2021

Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

Events

Jan 19, 2021
8:00 AM EST

Aclaris Therapeutics Presents Positive Preliminary Topline Data for ATI-450-RA-201

Dec 2, 2020
7:30 AM EST

Aclaris Therapeutics, Inc. at Evercore ISI 3rd Annual HealthCONx Conference

Sep 17, 2020
10:40 AM EDT

Aclaris Therapeutics, Inc. at Cantor Virtual Global Healthcare Conference

Feature Presentation

ATI-450-RA-201 Phase 2a Preliminary Topline Data Presentation

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2021 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.